Robert Harris research group
We aim to apply novel therapies derived from experimental studies into the human clinical setting.
The Applied Immunology group is dedicated to investigation of the pathogenesis of autoimmune diseases, including multiple sclerosis (MS), type I diabetes (T1DM) and rheumatoid arthritis (RA), and developing new therapies for use in these diseases. These represent some of the most common diseases in the Western World, and constitute a tremendous burden to health budgets worldwide. Currently used therapies have only a modest benefit for most patients, and the need for new therapeutic interventions is thus paramount. Through study of experimental diseases we aim to apply this knowledge to the human clinical situation.
We conduct a strongly interconnected research programme aimed at using knowledge gained from projects in basic science to applications in a clinical setting. These aims can be summarised as:
- Characterization of the immune mechanisms underlying autoimmune diseases
- Defining the biochemical and immunological basis of the autoantigenicity of self proteins
- Development of novel therapies to treat autoimmune diseases
Another major aim is the training of PhD students and postdoctoral fellows. We contribute to teaching in the undergraduate programs for Allergy, Immunology & Inflammation, Neuroscience and Biomedicine. Students and clinicians are welcome to conduct projects in the laboratory. The research laboratory is located in the Centre for Molecular Medicine (CMM) at the Karolinska Hospital. Within CMM, we collaborate with research groups in rheumatology, immunology, cell biology and other disciplines. We are also engaged in active collaborations with research groups at MTC, Huddinge Hospital and several international institutions.
- Post-translational modification of myelin proteins in pathogenesis of Multiple Sclerosis
- Personalised myeloid cell therapy for treatment of chronic autoimmune diseases
- Myeloid cells in treatment of glioblastoma multiformes brain tumours
Fatal demyelinating disease is induced by monocyte-derived macrophages in the absence of TGF-β signaling.
Nat. Immunol. 2018 05;19(5):1-7
BAFF-secreting neutrophils drive plasma cell responses during emergency granulopoiesis.
J. Exp. Med. 2016 07;213(8):1537-53
Adoptive transfer of immunomodulatory M2 macrophages prevents type 1 diabetes in NOD mice.
Diabetes 2012 Nov;61(11):2881-92
|Jinming Han||Graduate Student|
|Robert Harris||Research team leader, Professor|
|Gunborg Linnéa Palme||Graduate Student|
|Keying Zhu||Graduate Student|